PAVmed (PAVM) Prices 9.8M Share Common Offering for Gross Proceeds of Approx. $45M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
PAVmed Announces Pricing of $45 Million Public Offering of Common Stock
February 23, 2021 9:00 AM ESTNEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today announced the pricing of its previously announced underwritten public offering (the Offering) of approximately 9.8 million shares of its common stock for gross proceeds of approximately $45 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by PAVmed. The Offering is expected to close on or about February 25, 2021, subject to customary closing conditions. In addition, PAVmed has granted the underwriter of the Offering a 30-day option to purchase up to approximately 1.5... More
